Physician profile
Alexander E Kasatkin
NPI 1144270323
$2,105.36
in general payments reported to CMS, 2019-2025
10 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $348 · 2021: $225 · 2022: $389 · 2023: $208 · 2024: $347 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,156.08 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Mycarelink |
| Medtronic Vascular, INC. | $333.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $156.47 | 2020-2024 | Xarelto |
| Boston Scientific Corporation | $133.61 | 2022 | |
| Atricure, INC. | $123.89 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.08 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.92 | 2023 | Edarbi |
| Amgen INC. | $16.96 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kasatkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.